San Diego, CA, United States of America

Don Rogness

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Vividion Therapeutics, Inc.. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Don Rogness. Retrieved from https://idiyas.com/inventor/don-rogness

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Don Rogness: Innovator in Pharmaceutical Compositions

Introduction

Don Rogness is a notable inventor based in San Diego, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific diseases.

Latest Patents

Rogness holds a patent for pharmaceutical compositions comprising WRN helicase inhibitors. This patent discloses compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R, R, X, Y, Z, and W are defined within the patent. The compounds are recognized as inhibitors of WRN helicase and are useful in treating proliferative diseases, such as cancer. He has 1 patent to his name.

Career Highlights

Don Rogness is currently associated with Vividion Therapeutics, Inc., where he continues to innovate in the pharmaceutical sector. His work focuses on developing therapies that can significantly impact patient outcomes.

Collaborations

Some of his notable coworkers include Shota Kikuchi and Betty Lam, who contribute to the collaborative environment at Vividion Therapeutics, Inc.

Conclusion

Don Rogness exemplifies the spirit of innovation in the pharmaceutical industry, with his work paving the way for potential breakthroughs in cancer treatment.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…